The Korea Times close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Business
  • Tech
  • Bio
  • Companies
Finance
  • Companies
  • Economy
  • Markets
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
Entertainment
& Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
Sports
World
  • SCMP
  • Asia
Video
  • Culture
  • People
  • News
Photos
  • Photo News
  • Darkroom
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
Business
  • Tech
  • Bio
  • Companies
Wed, May 18, 2022 | 22:00
Bio
Samsung, SK responding to Omicron COVID-19 variant
Posted : 2021-12-01 17:05
Updated : 2021-12-01 17:32
Print Preview
Font Size Up
Font Size Down
International flight passengers wear face shields, facemasks and protective gloves as they head to a bus after arriving at Incheon International Airport, Nov. 30. Yonhap
International flight passengers wear face shields, facemasks and protective gloves as they head to a bus after arriving at Incheon International Airport, Nov. 30. Yonhap

By Baek Byung-yeul

Samsung Biologics, SK Bioscience, Celltrion, Seegene and other Korean biotech firms are responding to the latest COVID-19 variant called Omicron at a time when the new mutation could become an even greater concern than the Delta variant, according to companies Wednesday.

After the advent of the new mutation last week, the World Health Organization (WHO) designated the strain as a "variant of concern" (VOC) due to its unusually large number of mutations and rapid spread.

As many healthcare experts express concern that the new mutation could be more contagious than the Delta variant and more resistant to vaccines and treatments, local bio companies are accelerating the development of new products that can effectively respond to the Omicron variant.

Speculations are being made that Samsung Biologics, a manufacturer of U.S. biotech company Moderna's COVID-19 vaccine, could also manufacture the latter's upcoming version of the drug at its plant.

Moderna already announced it could produce and ship a modified version of vaccines that are effective against the Omicron variant within 100 days.

Samsung is currently manufacturing Moderna's vaccines at its Songdo plant after the two companies inked a contract during a South Korea-U.S. vaccine partnership event held in Washington, D.C., in May.

Moderna's vaccines produced here are used for both the Korean and overseas markets. In regard to the speculation, a Samsung Biologics official said, "We are not at liberty to comment."

SK Bioscience, which is currently developing its own COVID-19 vaccines, is also closely watching the situation of the spreading Omicron variant. The company is expected to respond as soon as the analysis of information on the latest variant is completed.

Celltrion, the only Korean company that succeeded in developing a COVID-19 treatment, launched a project to develop a new version capable of responding to the variant.

The company said it is developing an inhalable treatment combining its monoclonal antibody treatment Regkirona and CT-P63. The company already received an approval by the European Commission for its Regkirona COVID-19 treatment.

Among the Korean companies, developers of diagnostic kits are spearheading the response. SD Biosensor, best known for producing at-home COVID-19 test kits, said Tuesday that its test kits are effective in detecting all COVID-19 variants. The firm said users of its at-home test kit can get a result within 15 minutes showing whether or not they are positive to the Omicron variant.

Molecular diagnosis company Seegene also said its polymerase-chain-reaction-based test recognizes the mutations within four hours. The company said its diagnostic product can detect the variant in the very first stage of screening, helping public health officials rapidly isolate and contact-trace people who are infected.


Emailbaekby@koreatimes.co.kr Article ListMore articles by this reporter
 
  • Competition heats up in urban air mobility market
  • 5 Woori Bank branches open exclusively for foreign customers every Sunday
  • India's wheat export ban feared to raise prices of bread, instant noodles
  • The Collective brings 'Bootycandy' to Korea
  • As China says goodbye to 2023 Asian Cup, should Korea step in?
  • Immigrant voter turnout declines in local elections
  • Air Seoul to resume Incheon-Boracay flights next month
  • Ex-baseball coach accused of assault suspended for 100 games by KBO
  • Korean volunteer fighter in Ukraine doesn't regret his action despite facing imprisonment at home
  • Gov't urged to increase support for creators when K-culture is hot
  • BTS wins three Billboard Music Awards, marking 6th year to win an award BTS wins three Billboard Music Awards, marking 6th year to win an award
  • Le Sserafim member Kim Ga-ram's bullying allegations resurface Le Sserafim member Kim Ga-ram's bullying allegations resurface
  • Yeo Jin-goo offers glimpse of his role in new series 'Link: Eat, Love, Kill' Yeo Jin-goo offers glimpse of his role in new series 'Link: Eat, Love, Kill'
  • How did TikTok become main marketing tool for K-pop? How did TikTok become main marketing tool for K-pop?
  • 'Broker,' 'Decision to Leave' to kick off summer blockbuster season 'Broker,' 'Decision to Leave' to kick off summer blockbuster season
DARKROOM
  • 2022 Pulitzer Prize: Bearing witness to history

    2022 Pulitzer Prize: Bearing witness to history

  • Worsening drought puts millions at risk

    Worsening drought puts millions at risk

  • Our children deserve the best

    Our children deserve the best

  • End of mask mandates

    End of mask mandates

  • Rio Carnival returns after two-year hiatus

    Rio Carnival returns after two-year hiatus

The Korea Times
CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Location
  • Media Kit
  • Contact Us
  • Products & Service
  • Subscribe
  • E-paper
  • Mobile Service
  • RSS Service
  • Content Sales
  • Policy
  • Privacy Statement
  • Terms of Service
  • 고충처리인
  • Youth Protection Policy
  • Code of Ethics
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group